RegeneRx, HLB Therapeutics sign letter of intent for Phase 3 clinical trials in neurotrophic keratitis

July 20, 2022

RegeneRX Biopharmaceuticals and its US joint venture partner and licensee, HLB Therapeutics, signed a letter of intent this week with a global ophthalmology contract research organization to conduct a pair of Phase 3 clinical trials simultaneously beginning in the fall in the US and Europe for patients with neurotrophic keratitis.

Enrolment begins in Phase 2 study for therapeutic for persistent corneal epithelial defects

July 10, 2022

Kiora Pharmaceuticals announced it has enrolled the first patient as a part of a Phase 2 study evaluating KIO-201 topical eye drops in patients with PCED, a rare ocular surface condition characterized by non-healing wounds on the eye surface.

Ill-timed corneal crosslinking led to permanent changes in corneal structure in patients with keratoconus

May 29, 2022

The study evaluates three separate cases, each of which experienced irreversible changes in their corneal structure caused by challenges in getting timely treatment due to various reasons, including insurance, lost to follow up, and the COVID-19 pandemic.